<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00190411</url>
  </required_header>
  <id_info>
    <org_study_id>P010309</org_study_id>
    <nct_id>NCT00190411</nct_id>
  </id_info>
  <brief_title>Celiprolol in Patients With Ehlers-Danlos Syndrome, Vascular Type</brief_title>
  <official_title>Prevention of Vascular Complications by BetaBlocker Treatment in Vascular Ehlers-Danlos Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aventis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ehlers-Danlos syndrome vascular type (EDS-IV) is caused by a genetic defect of collagen type&#xD;
      III. Patient die (median 40 yrs) of vascular complications. There is no treatment. We showed&#xD;
      that arteries are thin and overloaded in this patients. We test the protective effect of&#xD;
      celiprolol on cardiovascular events in a 5 years, randomized, PROBE design&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      100 patients with verified EDS-IV syndrome are included. Patients are randomized to either&#xD;
      celiprolol (50 to 400 mg BID)or no treatment. Patients who are not randomized enter a&#xD;
      longitudinal survey of events. The hypothesis is a 50% reduction in the occurrence of&#xD;
      cardiovascular events under treatment, assessed by a blinded, independent events committee.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>reduction in the rate of major cardiovascular events in the treated group during a 5 years follow-up</measure>
    <time_frame>during de study</time_frame>
    <description>reduction in the rate of major cardiovascular events in the treated group during a 5 years follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerance, effect of drug on arterial parameters : diameter, IMT, stiffness.</measure>
    <time_frame>during the study</time_frame>
    <description>Tolerance, effect of drug on arterial parameters : diameter, IMT, stiffness.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>EHLERS-DANLOS SYNDROME, TYPE IV, AUTOSOMAL DOMINANT</condition>
  <condition>CHROMOSOME 2q31.2 DELETION SYNDROME</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Celiprolol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>celiprolol</intervention_name>
    <description>celiprolol</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>celiprolol? Dose ranging 100 to 400 mg, dose adaptation</other_name>
    <other_name>every 6 months by increment of 100 mg, based on tolerance</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Untreated controls excluding betablockers</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Proven disease,&#xD;
&#xD;
          -  No betablocker at inclusion if previous CV event&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        Criteria of not inclusion for the RIGHTEOUS group:&#xD;
&#xD;
          -  Patient having already presented an arterial break or a dissection and&#xD;
             treated(handled) by bétâ-blocking(surrounding).&#xD;
&#xD;
          -  Against indication in the use of CELIPROLOL:&#xD;
&#xD;
          -  Unchecked cardiac insufficiency by the treatment&#xD;
&#xD;
          -  cardiogenic shock&#xD;
&#xD;
          -  BAV of 2nd and 3rd not sailed degrees&#xD;
&#xD;
          -  angor of Prinzmetal&#xD;
&#xD;
          -  disease of the sine&#xD;
&#xD;
          -  bradycardia&#xD;
&#xD;
          -  pheochromocytoma untreated&#xD;
&#xD;
          -  low blood pressure&#xD;
&#xD;
          -  sentimentality in the CELIPROLOL&#xD;
&#xD;
          -  Antecedent of anaphylactic reaction&#xD;
&#xD;
          -  myasthenia&#xD;
&#xD;
          -  treatment by FLOCTAFENINE ( Idarac), Sultopride ( interactions ) In these two cases,&#xD;
             the patient can be included in the group followed by troop.&#xD;
&#xD;
        Criteria of not inclusion for both groups:&#xD;
&#xD;
          -  Refusal to participate in the study.&#xD;
&#xD;
          -  Impossibility to move.&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Woman in age to procreate without means of effective contraception.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre BOUTOUYRIE, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <removed_countries>
    <country>France</country>
  </removed_countries>
  <verification_date>March 2007</verification_date>
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 16, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>January 15, 2013</last_update_submitted>
  <last_update_submitted_qc>January 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Arteries</keyword>
  <keyword>ultrasonography</keyword>
  <keyword>Ehlers Danlos syndrome</keyword>
  <keyword>Cardiovascular disease</keyword>
  <keyword>beta adrenergic antagonists</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ehlers-Danlos Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celiprolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

